NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 06/30/23
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to RedosingGlobeNewsWire • 06/29/23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 06/28/23
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™GlobeNewsWire • 05/22/23
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023GlobeNewsWire • 05/11/23
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual MeetingGlobeNewsWire • 05/02/23
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023GlobeNewsWire • 02/14/23
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022GlobeNewsWire • 12/21/22
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare CompanyGlobeNewsWire • 10/21/22